The second dual GIP/GLP-1 receptor agonist, tirzepatide (previously known as LY3298176; marketed as Mounjaro® for T2DM and Zepbound® for obesity), is a 39-amino acid peptide acylated with a C20:0 fatty diacid moiety to lysine residue at position 20 with a molecular weight of 4.8 kDa [Figure 2, Table 1]. Here, GIP is linked to type 2 diabetes mellitus.